We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

20 hedge funds and large institutions have $55.6M invested in Indaptus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

54% more funds holding

Funds holding: 13 → 20 (+7)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

41% less capital invested

Capital invested by funds: $93.7M → $55.6M (-$38.1M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
20
Holders Change
+7
Holders Change %
+53.85%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
2
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.87M
2
EDRH
Edmond de Rothschild Holding
Switzerland
+$434K
3
Renaissance Technologies
Renaissance Technologies
New York
+$372K
4
Deutsche Bank
Deutsche Bank
Germany
+$294K
5
DMK
David M. Knott
+$248K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$13.4M
2
NC
Nexthera Capital
New York
-$2.47M
3
PVI
Pura Vida Investments
New York
-$895K
4
CC
Caxton Corporation
New Jersey
-$31K
5
UBS Group
UBS Group
Switzerland
-$31K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACP
1
Acuta Capital Partners
California
$14M – – –
ACA
2
Avoro Capital Advisors
New York
$11.3M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$8.88M – – –
MIH
4
Meitav Investment House
Israel
$8.61M +$11.6M +746 New
CAM
5
Cormorant Asset Management
Massachusetts
$4.17M – – –
MIFH
6
Migdal Insurance & Financial Holdings
Israel
$2.69M – – –
SAM
7
Sectoral Asset Management
Quebec, Canada
$1.83M – – –
Millennium Management
8
Millennium Management
New York
$1.39M +$1.87M +121 New
Renaissance Technologies
9
Renaissance Technologies
New York
$688K +$372K +24 +67%
Deutsche Bank
10
Deutsche Bank
Germany
$593K +$294K +19 +59%
CC
11
Caxton Corporation
New Jersey
$375K -$31K -2 -6%
EDRH
12
Edmond de Rothschild Holding
Switzerland
$329K +$434K +28 New
DMK
13
David M. Knott
$180K +$248K +16 New
UBS Group
14
UBS Group
Switzerland
$139K -$31K -2 -14%
OAM
15
Oxford Asset Management
United Kingdom
$116K +$155K +10 New
VF
16
Virtu Financial
New York
$88K +$124K +8 New
MC
17
Menta Capital
California
$78K +$108K +7 New
TI
18
Trexquant Investment
Connecticut
$73K +$92.9K +6 New
AS
19
Altshuler Shaham
Israel
$35K +$62K +4 New
Macquarie Group
20
Macquarie Group
Australia
$8K +$15.5K +1 New
IA
21
IFP Advisors
Florida
$1K – – –
EC
22
EcoR1 Capital
California
– -$13.4M -670 Closed
NC
23
Nexthera Capital
New York
– -$2.47M -123 Closed
PVI
24
Pura Vida Investments
New York
– -$895K -45 Closed
Morgan Stanley
25
Morgan Stanley
New York
– -$4K – –

INDP Hedge Fund Activity: Q4 2017 in Review

20 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2017, worth a combined $55.6M — down 41% from $93.7M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new INDP positions and 3 closed out — a net gain of 7 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.87M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $13.4M sold.

  • 20 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2017, up from 13 in Q3 2017.
  • Funds reported $55.6M of Indaptus Therapeutics stock for Q4 2017, down 41% quarter-over-quarter.
  • 10 funds opened new Indaptus Therapeutics positions in Q4 2017 and 3 closed out, a net change of +7 holders.
  • The largest Indaptus Therapeutics buyer in Q4 2017 was Millennium Management, an estimated $1.87M added.
  • The largest Indaptus Therapeutics seller in Q4 2017 was EcoR1 Capital, an estimated $13.4M sold.

Based on aggregated 13F filings for Q4 2017.